Contrast agent developer Advanced Magnetics has received a U.S. patent related to the company’s next-generation iron oxide technology, which could be used for either MR angiography contrast agents or for therapy products.
The company’s patent covers heat-stable colloidal iron oxides coated with reduced carbohydrates and carbohydrate derivatives, the Cambridge, MA-based company reported. The patent covers various aspects of the company’s core carbohydrate-coated iron oxide technology, including its product in development, ferumoxytol.
Ferumoxytol is in phase II clinical trials for use as an iron replacement therapeutic in patients with chronic kidney disease who are receiving erythropoietin therapy. The agent is also in phase II clinical trials for use as a contrast agent in MRA, and in exploratory studies for the imaging of vulnerable plaque. Phase III clinical trials for iron therapy and MRA are expected to begin in late 2003 or 2004, the firm said.
By AuntMinnie.com staff writersJuly 31, 2003
Related Reading
Advanced Magnetics turns Q3 profit, July 16, 2003
Combidex shows promise with breast, prostate cancer, July 15, 2003
Advanced Magnetics sets $10 million stock sale, July 3, 2003
Advanced Magnetics falls into red in Q1, January 16, 2003
MRI agent detects lymph node disease in prostate and renal cancers, December 4, 2002
Copyright © 2003 AuntMinnie.com
